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Candida species are normal commensal organisms found in the skin, mouth, and 
gastrointestinal and genitourinary tracts of humans. Candida albicans is a normal 
component of the gut flora, and the oral and genital cavities. However, this organism is 
an opportunistic pathogen and it is one of the most frequently isolated species from 
patients with nosocomial fungal infections. Candida infections have grown in recent 
years due to antimycotics resistance and the extensive use of antibiotics. This has pushed 
scientists to look for alternative therapeutic agents to treat fungal infections.  
Yeasts can produce toxic proteins called “mycocins” or “killer toxins” that can 
kill sensitive yeast species. The production of killer toxins is a phenomenon widely 
spread among yeast species. Debaryomyces hansenii, a yeast commonly found in 
cheeses, produces killer toxins that are able to kill the strains of Candida albicans 
SC5314 and Candida tropicalis NRRL-10985 at optimum conditions of 20C and pH 
4.5. The use of Debaryomyces hansenii as a biotechnological agent has been suggested, 
but the amount of toxins produced, and the genetic basis and mechanism of action of 
these toxins, remains a mystery. 
To study the extent of pathogenic Candida species affected by this toxin, nineteen 
strains of Debaryomyces hansenii were tested for killer activity against Candida species, 
previously isolated from patients with bloodstream infections, by streak-plate agar 
diffusion bioassay. The killer activity of Debaryomyces hansenii killer strains was also 
tested against Debaryomyces hansenii non-killer strains. Additionally, to understand the 
nature of these toxins, 2x250 paired end Illumina sequencing was performed in 6 killer 
and 3 non-killer strains of Debaryomyces hansenii previously isolated from different 
types of cheeses. Numerous differences among the strains were found. Primers and 
protocols were designed to knockout presumptive genes and confirm their relationship 
with toxicity. 
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“Our greatest weakness lies in giving up. The most certain way to succeed  
is always to try just one more time.” 
-Thomas A. Edison 
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Chapter 1 
Killer yeast phenomenon: Debaryomyces hansenii mycocin production 
and its applications. 
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1.1 Killer Yeasts 
Makower and Bevan first discovered the killer character in Saccharomyces cerevisiae 
in 1963 (Woods and Bevan 1968). Killer yeasts produce toxic proteins or glycoproteins 
(also called mycocins), and this characteristic has been found in more than 90 yeast 
species across more than twenty genera (Table 1.1) (Polonelli et al. 1991; Walker et al. 
1995; Young and Yagiu 1978). Killer yeasts are able to kill sensitive yeast species by 
several biological pathways and the genetic basis of the killer phenotype can be 
chromosomal or cytoplasmic, encoded on double stranded RNA virus-like particles or 
linear double stranded DNA plasmids (Magliani et al. 1997). Moreover, as a self defense 
mechanism they possess intrinsic immunity to the action of their own mycocins (Schmitt 
and Breinig 2002). However, there exist situations where mycocin concentration prevails 
and this immunity is overcome, e.g., so-called suicidal mutants (K+ R–) (Polonelli et al. 
1991).  
Young stated that while all killer systems vary, they have a proteinaceous compound 
crucial to the mycocin activity that is common among them, and yeasts from the same 
species can produce several toxins with different modes of action (Young and Yagiu 
1978). The reason behind killer toxin production is not fully understood; however, it is 
possible that killer yeasts produce these components when found in a competitive 
ecological niche to ensure survival of the species or strain (Polonelli et al. 1991). 
Hodgson agrees with Polonelli and states that these toxins might differ biochemically in 
response to ecological interaction with sensitive strains; i.e. killer strains will lose the 
ability to generate killer toxins if these are not essential for survival (Hodgson et al. 
1995).  
   
3 
1.2 Killer toxins modes of action 
The first step to achieve lethality on a susceptible organism is commonly a cell wall 
receptor on the sensitive cell that interacts with the killer toxin (usually chitin, -glucans 
or mannoproteins) and suggestions exist about the existence of a second receptor on the 
plasma membrane that facilitates absorption (Magliani et al. 1997; Schmitt and Breinig 
2006). Subsequently, they can achieve a lethal effect by different biological pathways. 
They can induce changes in the permeability of the membrane by forming an ion channel, 
leading to uncontrolled leakage of protons, potassium ions, amino acids and ATP 
molecules causing cell death (Marquina et al. 2002). Alternatively, they can release 
signals that will result in inhibition of DNA synthesis causing a lethal effect (Liu et al. 
2015).  Several authors explain the relationship between attacking the tRNA and cell 
death in the killer activity that Kluyveromyces lactis exhibits towards Saccharomyces 
cerevisiae (Frohloff et al. 2001; Jablonowski and Schaffrath 2007; Jablonowski et al. 
2006). Additionally, a pathway blocking calcium uptake results in inhibition of cell 
growth and division (Liu et al. 2015). Figure 1.1 illustrates several mechanisms of action 
of these killer toxins.  
Killer toxins are usually temperature and pH dependent (Banjara et al. 2016; Magliani 
et al. 1997). Studies show that the common pH for killer toxin stability is between 2.0 
and 4.5, and there exist some organisms for which toxin production is irreversibly 
inactivated above pH 5.0 (Young and Yagiu 1978). 
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Figure 1.1 Schematic of different killer toxins modes of action  
                   (Liu et al. 2015). 
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1.2.1 Saccharomyces cerevisiae killer system 
Saccharomyces cerevisiae, in which the killer phenomenon was first described, is 
the most thoroughly studied killer system. It produces several mycocins: three are 
cytoplasmically encoded on dsRNA virus-like molecules (K1, K2 and K28) and two are 
encoded on chromosomal DNA (KHS and KHR) (Magliani et al. 1997; Young and Yagiu 
1978). Killer yeasts, as a self-protection mechanism, are normally immune to the action 
of their own mycocins (Bussey 1991; Schmitt and Breinig 2006). However, S. cerevisiae 
killer strains can present themselves as suicidal mutants (killer positive, resistance 
negative K+ R–) that produce killer toxins but exhibit a reduced immunity and when 
killer toxin concentration is higher than 100-fold it results in a lethal effect, as well as 
normal killer strains (K+ R+) and sensitive strains (K- R-) (Polonelli et al. 1991). Neutral 
mutants (K– R+) – resistant strains that do not produce killer toxins – also exist (Polonelli 
et al. 1991).  
K1 toxin (19 kDa) is a disulfide-linked dimer ( and ) that acts on the 
susceptible species by a two-step mechanism. First, the toxin binds to the -(16) 
glucans on the sensitive strain’s cell wall; this step is dependent on a pH of 4.6. The 
second step consist of forming an ion channel that increases the permeability of the 
membrane, allowing leakage of protons and potassium ions followed by amino acids and 
ATP molecules, resulting in cell death (Bussey 1991; Magliani et al. 1997). K2 toxin 
presents the same mode of action as K1 although it is a different two-subunit protein with 
a molecular weight of 21.5 kDa. However, killer toxin K28, which forms a heterodimer 
and has a molecular weight of 21.5 kDa, possesses a different mode of action. The first 
step consists of binding to the -1,3-mannoproteins (Schmitt and Breinig 2002). The 
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second step involves stopping DNA synthesis by blocking G1 phase, which provides a 
lethal effect (Marquina et al. 2002). The modes of action for toxins KHR and KHS are 
unclear, but Magliani indicates the possibility of KHS working by ion-channel formation 
similarly to K1 and K2 (Magliani et al. 1997). 
 
1.2.2 Kluyveromyces lactis killer system 
Plasmids in yeasts are either dsRNA, circular DNA or linear DNA (Fukuhara 
1995). Gunge et al. discovered the Kluyveromyces lactis killer phenotype while searching 
for plasmids in yeasts (Gunge et al. 1981). K. lactis killer strains have been found to 
exhibit the killer phenotype against several genera and species including Saccharomyces, 
Candida and K. lactis non-killer strains (Gunge et al. 1981).  
K. lactis possesses two plasmids, pGKL1 and pGKL2, with pGKL2 being 
necessary for pGKL1 maintenance and replication. The killer toxin produced by this 
organism, as well as the immunity region, are encoded on the linear double stranded 
DNA plasmid pGKL1 (Fukuhara 1995). The killer toxin consists of a 156 kDa trimer 
(Figure 1.2) with subunits ,  and  (Liu et al. 2015). Four open reading frames (ORFs) 
have known functions in pGKL1 (Table 1.4), with ORF2 and ORF4 coding for the 
predecessor of the mycocin and ORF3 providing the immunity determinant (Magliani et 
al. 1997). The mode of action of this toxin is not well comprehended. However, it is 
known that the toxin binds to the chitin component of the cell wall in the susceptible 
strain and results in cell cycle arrest at the G1 phase (Magliani et al. 1997). 
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Figure 1.2 Structure of the two plasmids of Kluyveromyces lactis killer system. The 
two linear DNA plasmids, pGKL1 and pGKL2, of K. lactis are shown schematically. In 
pGKL1, ORF1 is thought to code for a DNA polymerase, ORF2 and 4 for three toxin 
subunits ,  and , and ORF3 for immunity (resistance to toxin) determinant; In pGKL2, 
ORF2, 4 and 6 are thought to code for a DNA polymerase, a helicase and an RNA 
polymerase, respectively; TGF1 has a role in plasmid replication. The terminal proteins 
are believed to be covalently attached to the DNA ends. IR, inverted terminal repeats 
(Fukuhara 1995).  
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1.2.3 Williopsis mrakii killer system 
Williopsis mrakii produces two killer toxins encoded on chromosomal DNA, 
namely, HMK and K-500 (Magliani et al. 1997; Marquina et al. 2002). HMK, also 
referred to as HK-1, is a 10.7 kDa polypeptide rich in cysteine residues, and disulfide 
bonds seem to be the cause of its pH and thermostability; stable at pH 2-11, and at 100C 
for 10 min (Magliani et al. 1997). Its killing activity is associated with the inhibition of -
1,3-glucan synthesis (Marquina et al. 2002). The second toxin, K-500, is a small 
polypeptide, 5.0 kDa, that exhibits killer activity against Candida species presumably by 
ion channel formation (Magliani et al. 1997).  
 
1.2.4 Ustilago maydis killer system 
The killer character in Ustilago maydis is encoded on dsRNA virus like particles 
(Koltin and Day 1976). U. maydis produces three different toxins, KP1, KP4 and KP6, 
with the last being the best studied (Finkler et al. 1992). KP6 killer toxin consists of two 
polypeptides,  (8.6 kDa) and  (9.1 kDa) (Magliani et al. 1997). Its mechanism of action 
is unknown. The  subunit is rich in cysteine and the disulfide bonds are crucial for its 
activity, presumably ion channel formation. Furthermore, the  subunit needs to interact 
with the cell wall so that the  subunits can cause the lethal effect (Steinlauf et al. 1988). 
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Table 1.1 Characteristics of the yeast killer toxins (Marquina et al. 2002). 
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1.3 Killer toxins applications  
Numerous applications for killer yeasts have been proposed over the years (Table 
1.2). Scientists have suggested their use as biocontrol agents against wood-decay and 
plant pathogenic fungi (Walker et al. 1995). Inhibition of spoilage organisms in the food 
industry is an important application that has been widely studied (Palpacelli et al. 1991), 
and special attention has been given within the wine industry due to the low pH required 
for the killing activity to occur (Heard and Fleet 1987; Jacobs et al. 1988; Tredoux et al. 
1986). Santos looked at PMKT2 killer toxin produced by Pichia membranifaciens 
(Santos et al. 2009), and KP6 killer toxin produced by Ustilago maydis (Santos et al. 
2011) and demonstrated the potential of both organisms as biocontrol agents to inhibit the 
growth of the spoilage yeast Brettanomyces bruxellensis in wine fermentations, due to the 
resistance that Saccharomyces cerevisiae exhibits towards these toxins. Also, he studied 
inhibition of Botrytis cinerea (a mold) by P. membranifaciens killer toxin in apples 
(Santos et al. 2004), and proposed its use as a biological control. The yeast Williopsis 
saturnus var. saturnus, which is incapable of fermenting lactose and/or galactose, was 
investigated for its potential as a biopreservative in cheese (Liu and Tsao 2009). Even 
inhibition of pathogenic bacteria like Listeria monocytogenes by food-borne yeasts has 
been investigated (Goerges et al. 2006). 
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Table 1.2 Potential applications of killer toxins. 
Biotechnological field of 
application  
Application 
Biological control in agriculture Antifungal activity against wood-decay and plant 
pathogenic fungi. Prevention of aerobic spoilage of 
silage. 
Beverage fermentation Avoid undesired contamination in wine, beer, sake, 
etc. 
Cellular biology research on 
eukaryotic cells 
Studies of biosynthesis, cellular processing and 
secretion of proteins. 
Food technology Food preservatives of natural origin. 
Genetics Selection of hybrids obtained by protoplast fusion. 
Fingerprinting of wine yeasts. Recombinant DNA 
technology (cloning vectors). 
Medicine Killer activities against pathogenic yeasts. 
Taxonomy Killer toxin sensitivity patterns may be indicative 
of phylogenetic affiliation. 
Source (Marquina et al. 2002) 
 
Moreover, researchers that have found killer activity against human pathogenic 
strains have encouraged the study of these organisms for the possible treatment of 
diseases (Banjara et al. 2016; Liu et al. 2015; Polonelli et al. 1986). The antifungal drug 
amphotericin B that is used to treat yeast infections (Vyas and Gupta 2006) induces 
permeability of ions through the membrane when used at high concentrations, which 
causes the antifungal antibiotic effect (Polonelli et al. 1991). This is similar to the mode 
of action of some killer toxins. Antifungal therapy against yeast infections can be 
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ineffective due to emerging resistance, and more treatment options are needed due to 
the increase in nosocomial infections among immunocompromised patients (Sobel 2006).  
 
1.4 Debaryomyces hansenii 
Debaryomyces hansenii (also identified in the literature as Candida famata, although 
it is probably a distinct but closely related species (Dmytruk and Sibirny 2012)) is a 
haploid yeast that reproduces by multilateral budding (Breuer and Harms 2006). It 
possesses many characteristics that make it an important yeast for biotechnological 
applications. The ability to synthesize and accumulate lipids, making it a so-called 
oleaginous yeast, has been studied by several scientists (Merdinger and Devine 1965; 
Tunblad-Johansson et al. 1987). The synthesis of D-arabitinol (Anderson and Harris 
1963) and the capability to use inorganic ammonium as a nitrogen source (Breuer and 
Harms 2006; Yanai et al. 1994) are commercially attractive. D. hansenii produces large 
quantities of xylitol (Parajó et al. 1997; Roseiro et al. 1991), a sugar alcohol used in 
sugar-free foods due to its intense sweet taste (Sardesai and Waldshan 1991), diabetics’ 
tolerance towards it, and anti-cavity properties (Isokangas et al. 1988). It also produces 
volatile compounds that are favorable for flavor development in dry-cured meat products 
(Andrade et al. 2010) and cheeses (Gori et al. 2012). Moreover, D. hansenii is an 
extremophile, one of the most halotolerant yeast species, growing in media containing up 
to 4M NaCl (Breuer and Harms 2006). It was originally isolated from saline 
environments (Kumar et al. 2012) and is among the most common yeasts found in cheese 
(Banjara et al. 2015) and in dry–cured meat products (Andrade et al. 2009). D. hansenii 
can also be found in environments with low water activity; hence its association with soil, 
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fruits, wine and beer (Breuer and Harms 2006; Kumar et al. 2012). D. hansenii exhibits 
considerable genetic diversity between strains (Corredor et al. 2003), reflected in the 
number of carbon substrates for which assimilation is denoted “variable” (Table 1.3). D. 
hansenii grows poorly in anaerobic conditions, contributing to the inability of some 
strains to ferment lactose, and leading to weak fermentation of galactose, sucrose, 
glucose, maltose and raffinose (Breuer and Harms 2006).  
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Table 1.3 Assimilation of substrates by Debaryomyces hansenii. 
 
 
      + = positive, W = weak, V = variable, – = negative 
                  Source (Breuer and Harms 2006) 
 
 
 
 
Glucose + N-Acetyl-D-glucosamine V 
Galactose + Methanol – 
L-Sorbose V Ethanol +/W 
Sucrose + Glycerol + 
Maltose + Erythritol V 
Cellobiose + Ribitol + 
Trehalose + Galacitol V 
Lactose V D-Mannitol + 
Melibiose V D-Glucitol +/W 
Raffinose + -Methyl-D-glucoside + 
Melezitose V Salicin +/W 
Inulin V D-Gluconate +/W 
Soluble starch V DL-Lactate V 
D-Xylose + Succinate + 
L-Arabinose +/W Citrate V 
D-Arabinose V Inositol – 
D-Ribose V Hexadecan V 
L-Rhamnose V Nitrate – 
D-Glucosamine V Nitrite V 
2-Keto-D-gluconate + 5-Keto-D-gluconate V 
Saccharate –   
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1.4.1 Debaryomyces hansenii killer toxin production 
Strains of Debaryomyces hansenii exhibit the killer phenotype and have been 
found to tolerate killer toxins from Kluyveromyces lactis, Candida zeylanoides and 
Trichosporon cutaneum (Fukuhara 1995; Nout et al. 1997). This suggests possible 
applications in food fermentations and preservation (Santos et al. 2002) and as a 
therapeutic agent (Banjara et al. 2016; Buzzini and Martini 2001). The genetic basis of 
the killer activity in Debaryomyces hansenii is unknown. Gunge reported the presence of 
three plasmids, pDHL1, pDHL2 and pDHL3, in D. hansenii (Gunge et al. 1993). Linear 
plasmid pDHL3 is essential for the replication of plasmids pDHL1 and pDHL2 (Fukuda 
et al. 1997). Plasmid pDHL1 is highly homologous to the plasmid pGKL1 present in 
Kluyveromyces lactis (Table 1.4), in which the linear dsDNA plasmid pGKL1 encodes a 
protein that is responsible for the killer phenotype (Fukuda et al. 1997; Gunge et al. 1993; 
Magliani et al. 1997). Santos and Marquina (Santos et al. 2002) were unable to eliminate 
the killer phenotype with various treatments used to eliminate plasmids (exposure to high 
temperatures, ultraviolet light and cycloheximide) and therefore concluded that the killer 
factor is chromosomally encoded. They reported that the killer toxin is a low molecular 
weight secreted protein, and identified 16--D-glucan as the cell wall binding site for 
this killer toxin. However, it is unknown if additional toxins may exist, as is the case of 
Saccharomyces cerevisiae, or how the killing mechanism of any of these toxins is 
achieved. 
Corredor and colleagues reported high genome variability between strains of 
Debaryomyces hansenii based on chromosomal rearrangements and repeated and deleted 
sequences (Corredor et al. 2003). Banjara’s work agrees with Corredor’s findings, in so 
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far as D. hansenii isolates from cheese showed consistent, reproducible variation in 
killer toxin activity, suggesting genetic differences between them. Furthermore, his work 
confirmed reports from Marquina and colleagues (Marquina et al. 2001), where it was 
revealed that the killer activity is pH and temperature dependent with optimum conditions 
at 20C and pH 4.5, and extended the findings to multiple D. hansenii strains (Banjara et 
al. 2016).  
Mycocins produced by the cheese-derived yeast Debaryomyces hansenii represent 
an interesting area of research due to their ability to kill human fungal pathogens Candida 
albicans and Candida tropicalis in vitro. It is evident that more research is needed to 
understand the mechanisms by which these mycocins kill Candida species, so as to be 
able to use them as therapeutic agents for the possible treatment of fungal infections. 
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Table 1.4 Relatedness of gene sequences of the linear plasmids vs. K. lactis killer plasmids (Fukuhara 1995). 
 
Host 
 
Plasmid 
pGKL1 gene probes pGKL2 gene probes 
ORF1 
(DNA pol) 
ORF2a 
(toxin ) 
ORF2 
(tox.  + ) 
ORF3 
(immun.) 
ORF4 
(toxin ) 
ORF2 
(DNA pol) 
ORF6 
(RNA pol) 
K. lactis pKL2A + + + + + + + + + + + + + + + – – 
 pKL2B – – – – – + + + + + + 
W. robert. pWR1A – + + – – – – 
 pWR1B – – – – – + + 
D. hansen. pDH1A + + + – – – – 
 pDH1B – – – – – + + 
P. etchel. pPE1A – – – – – – – 
 pPE1B – – – – – – + 
Three pairs of linear plasmid DNAs were examined for the presence of homology with K. lactis killer DNA genes. Each DNA was 
hybridized with labeled individual gene probes from the K. lactis killer plasmids pGKL1 and 2. Data were taken from (Cong et al. 
1994); + and – indicate presence and absence of hybrid signals, respectively. + + + corresponds to the intense signal of homologous 
hybridization at the same stringency condition. ORF2a is the N-terminal half of ORF2, coding for the toxin subunit . K. lactis = 
Kluyveromyces lactis, W. robert = Wingea robertsiae, D. hansen = Debaryomyces hansenii, P. etchel = Pichia etchellsii.  
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1.5 Candida species as human pathogens 
Candida species are commensal yeasts of the human skin, mouth, gut, and vagina 
(Figure 1.3) that usually cause no harm in healthy individuals. However, when the host 
system is altered, i.e. the immune system is suppressed, they take advantage and become 
pathogenic (see Table 1.5 for risk factors). Infections caused by Candida yeasts (known 
as candidiasis) can range from mild cutaneous lesions and mucosal infections to severe 
systemic infections (bloodstream infections, i.e., candidemia, and invasive candidiasis, 
[IC]). Candida albicans is the most commonly isolated pathogenic species from 
infections, but there are other clinically important species such as C. glabrata, C. 
parapsilosis, C. krusei and C. tropicalis, which are also frequently found in patients with 
fungal infections (Papon et al. 2013; Suhr 2015). Candida is the most common cause of 
hospital-acquired fungal infections (see Table 1.7 for species breakdown) and is 
responsible for up to 40% mortality rate (Alonso-Valle et al. 2003). The incidence of 
yeast infections continues to increase every year (Table 1.6), probably due to the 
extensive use of antibiotics and an increasing population of immunosuppressed 
individuals. Additionally, drug-resistant species and strains are increasing in prevalence 
(Sobel 2006). Hence, biological controls constitute a valuable possibility for the 
treatment of these diseases. 
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Table 1.5 Major risk factors for invasive Candida infections (Perlroth et al. 2007). 
Iatrogenic/Nosocomial Conditions* Immunosuppression* 
Colonization Neutropenia 
Broad spectrum antibiotics Corticosteroids 
Central venous catheter HIV‡ 
Parenteral nutrition Diabetes mellitus‡ 
Gastrointestinal or cardiac surgery  
Prolonged hospital stay†  
ICU stay  
Burns  
Premature neonate  
                    *Many iatrogenic/nosocomial conditions are accompanied by poorly     
                      characterized immune defects (e.g., burn injuries and surgery down  
                      modulate normal host defense mechanisms), as is diabetes mellitus.  
                    ‡HIV and diabetes mellitus predominantly predispose to mucocutaneous  
                     candidal infections, and diabetes is also a risk factor for disseminated  
                     disease; HIV is a cofactor for, but not an independent risk factor for,   
                     disseminated disease. 
                   †Mean time to onset of disease in a recent, large, prospective study was  
                     day 22 of hospitalization. 
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Table 1.6 Trends in bloodstream infections caused by yeasts (Hazen 1995). 
Year of 
Review 
Summary and comments Reference 
1985 Studied only candidemia; frequency of species was C. 
albicans > C. tropicalis > C. parapsilosis > C. glabrata > 
C. krusei > other species 
(Horn et al. 
1985) 
1986 Concerned with Virginia hospitals; found increase in 
Candida infections between 1978 and 1984 from 0.1 to 1.5 
cases/10,000 patient discharges 
(Morrison et 
al. 1986) 
1989 Ranked nosocomial bloodstream infections; from 1984 to 
1988, Candida species changed from eight to fourth most 
common agent of infection; genera of gram-negative bacilli 
are considered as individual categories 
(Pfaller 1989) 
1991 Candida species are fifth leading cause of bloodstream 
infection in 1989 (up from sixth in 1980) if gram-negative 
bacilli are considered one group  
(Banerjee et 
al. 1991) 
1991 Survey on fungemia for 1989 in one hospital in South 
Africa found that 2.1% of blood cultures contained yeasts; 
these included C. albicans (42%), C. tropicalis (26%),      
C. parapsilosis (20%), C. glabrata (7%), Hansenula spp. 
(2%), C. guilliermondii (1%), and C. krusei (1%).  
(Badenhorst 
et al. 1991) 
1992 Retrospective study in Indian teaching hospital; compared 
5-yr periods 1980-1985 and 1986-1990; found 11-fold 
increase in candidemia; most common species isolated 
were C. albicans, C. tropicalis, C. parapsilosis, and          
C. guilliermondii 
(Chakrabarti 
et al. 1992) 
1992 Fungemia isolates in one hospital between 1984 and 1990; 
C. albicans > C. tropicalis = C. glabrata > C. krusei >      
C. parapsilosis = C. guilliermondii 
(Meunier et 
al. 1992) 
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Figure 1.3 The human mycobiota (Underhill and Iliev 2014). 
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Table 1.7 Species breakdown of disseminated candidiasis (Perlroth et al. 2007). 
Species Percent of cases 
Candida albicans ≈ 50% 
Candida glabrata ≈ 15 – 25%  
Candida parapsilosis ≈10 – 20% 
Candida tropicalis ≈ 15% 
Candida krusei* ≈ <3% 
Others ≈ <5% 
         *At cancer centers where significant fluconazole prophylaxis is used, C. krusei    
           incidence may cause up to 10 – 15% of disseminated candidiasis. 
 
 
1.5.1 Candida albicans 
Candida albicans is the most commonly isolated species from patients with 
invasive infections, being responsible for 50% of Candida infections (Perlroth et al. 
2007). It possesses a range of virulence factors (dimorphism, adhesins and invasins, 
formation of biofilms, secretion of hydrolytic enzymes) and fitness attributes (rapid 
stress, pH change and nutrient deficit adaptation) that account for its pathogenicity 
(Mayer et al. 2013). Dimorphism is the ability of the organism to change from a yeast 
form to hyphal form (Jacobsen et al. 2012). The yeast disseminates through the body and 
subsequently the formation of the hyphae expresses genes that encode for virulence 
factors (Mayer et al. 2013). Adhesins are proteins that facilitate the adherence of C. 
albicans to the cell surface, which is the first step towards infection (Garcia et al. 2011; 
Tsai et al. 2013). There are three different hydrolases produced by C. albicans: lipases, 
phospholipases and proteases (Williams et al. 2013). These hydrolytic enzymes help to 
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disseminate the infection (Wächtler et al. 2012) and in nutrient acquisition (Naglik et 
al. 2003). Additionally, biofilm formation is an important virulence factor. Biofilms are 
resistant to antimicrobials and antifungals, and the accumulation of yeast cells in medical 
equipment, e.g., catheters, present a serious risk for immunocompromised patients 
(Fanning and Mitchell 2012).  
 
1.5.2 Candida glabrata 
Candida glabrata is the second most common Candida species isolated from 
patients with candidemia in the US and Europe, accounting for 15 – 25% of Candida 
infections (Perlroth et al. 2007; Pfaller et al. 1998). It is closely related to Saccharomyces 
cerevisiae, unlike other Candida species (Roetzer et al. 2011). C. glabrata infections are 
more common in adults and are associated with azole prophylaxis, surgery and catheters 
(Krcmery and Barnes 2002). C. glabrata is resistant to azoles, which are the most 
commonly used antifungals due to their effectiveness against other Candida species. 
However, it is vulnerable to other antifungals like amphotericin B (Fidel et al. 1999).  
 
1.5.3 Candida tropicalis 
Candida tropicalis is responsible for 10 – 20% of Candida infections (Perlroth et 
al. 2007). It is among the most common non-Candida albicans Candida (NCAC) species 
isolated from infections (Negri et al. 2011) and it has been presenting resistance to 
fluconazole (Kothavade et al. 2010). Taxonomically speaking C. tropicalis is closely 
related to C. albicans (Negri et al. 2011). The rate of infections is correlated with several 
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risk factors including cancer, antibiotics, prolonged stay in hospitals, neutropenia and 
bone marrow transplants (Krcmery and Barnes 2002; Negri et al. 2011).  
 
1.5.4 Candida parapsilosis  
Candida parapsilosis accounts for 10 – 20% of Candida infections (Perlroth et al. 
2007). Infections are a threat mostly to neonates and are related to hyperalimentation and 
body insertions (catheters) (Kojic and Darouiche 2004; Silva et al. 2012).  
 
1.6 Anti-Candida activity by killer yeasts 
Killer yeasts are known to have antimicrobial effects over sensitive species. 
Williopsis mrakii, Hanseniaspora uvarum and Hansenula anomala are a few of the yeast 
that exhibit anti-candida activity (Hodgson et al. 1995; Schmitt et al. 1997).  More 
recently, killer toxin produced by marine-derived yeast Wickerhamomyces anomalus has 
been found to produce killer toxins against C. albicans and C. tropicalis at pH 3.5 and 
16C (Guo et al. 2013), and food-derived yeast Debaryomyces hansenii has been found to 
produce killer toxins against C. albicans and C. tropicalis at pH 4.5 and 20C (Banjara et 
al. 2016). Killer toxins depend on pH and temperature for their action, and these differ 
between species; being prevalent low pH and temperature (~20C) for the killing activity. 
Most of the studies in killer yeasts have been performed in vitro, especially those 
against Candida species. Killing in vivo has not yet been reported. The human body 
temperature is 37C and due to the low temperature needed for the killing activity of 
mycocins to occur, the therapeutic use of these toxins in vivo presents a challenge. To be 
able to use killer toxins as antifungals, the toxin would need to overcome several 
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obstacles, including being active at 37C, surviving the acidity of the stomach and 
finally reaching the lower gastrointestinal tract, which is where most of the drugs are 
absorbed (Martinez and Amidon 2002).  
Nonetheless, this presents itself as an important research field. The extensive use of 
antibiotics, the increase in the number of immunocompromised patients and the amount 
of pathogens becoming resistant to antifungals are some of the reasons why yeast 
infections are continuing to increase every year (Hazen 1995; Pfaller 1989; Sobel 2006).  
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Chapter 2 
Effect of Debaryomyces hansenii killer toxin against pathogenic 
bloodstream Candida isolates. 
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2.1 Abstract 
Candida species are commensal organisms (part of the normal human 
microbiota), but when the host immune system is disrupted they can become pathogenic. 
Antifungal therapy against yeast infections can be ineffective due to emerging resistance 
correlated with their prolonged use, and more treatment options are needed. Yeast 
production of toxic proteins or glycoproteins, i.e. killer toxins or mycocins, was first 
discovered in Saccharomyces cerevisiae, and it has been observed in more than 90 
species. One of the applications of killer toxins is in the field of biotechnology, as is the 
case for Debaryomyces hansenii, which was found to produce toxins against common 
human fungal pathogens Candida albicans (SC5314) and Candida tropicalis (NRRL-
10985). However, the extent of yeast species and strains susceptible to D. hansenii’s 
toxin(s), and the nature of this susceptibility, remain unknown. To expand the knowledge 
on the extent of pathogenic Candida species susceptible to Debaryomyces hansenii killer 
toxin, nineteen D. hansenii strains were assayed for killer activity against nine 
bloodstream isolates from six pathogenic yeast species. No strain had any effect on 
bloodstream Candida albicans, Candida parapsilosis or Candida orthopsilosis under the 
conditions tested. The single Wickerhamomyces anomalus strain was susceptible to the 
same D. hansenii strains that killed Candida tropicalis NRRL-10985, and Candida 
glabrata presented an unusual, but very interesting susceptibility pattern. Additionally, D. 
hansenii strains were assayed for killing activity against each other, with no such activity 
detected. Finally, protein biosynthesis was inhibited with cycloheximide so as to 
investigate whether the toxin was coded cytoplasmically or chromosomally. Killer toxin 
assay on samples treated with cycloheximide suggests that the toxin is encoded in the 
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chromosome (instead of cytoplasmically) and that there exist numerous differences 
between D. hansenii strains that may account for the difference in toxicity. 
 
2.2 Introduction 
Candida species are commensal yeasts of the human skin, mouth, gut and vagina, 
usually causing no harm in healthy individuals. However, when the host system is 
altered, i.e. the immune system is suppressed, they take advantage and become 
pathogenic. Infections caused by Candida yeasts (known as candidiasis) can range from 
mild cutaneous lesions and mucosal infections to severe systemic infections (bloodstream 
infections, i.e., candidemia, and invasive candidiasis, [IC]). Candida albicans is the most 
commonly isolated pathogenic species from infections, but there are other clinically 
important species such as C. glabrata, C. parapsilosis, C. krusei and C. tropicalis, which 
are also frequently found in patients with fungal infections (Papon et al. 2013; Suhr 
2015). The incidence of yeast infections continues to increase every year, probably due to 
the extensive use of antibiotics and an increasing population of immunosuppressed 
individuals. Additionally, drug-resistant species and strains are increasing in prevalence 
(Sobel 2006). Hence, biological controls constitute a valuable possibility for the 
treatment of these diseases. 
Makower and Bevan first discovered the killer character in Saccharomyces 
cerevisiae in 1963 (Woods and Bevan 1968). Killer yeasts produce toxic proteins or 
glycoproteins (also called mycocins), and this characteristic has been found in more than 
90 yeast species (Buzzini and Martini 2001; Young and Yagiu 1978). Killer yeasts are 
able to kill sensitive yeast species and they possess intrinsic immunity to the action of 
    
40 
their own mycocin (Schmitt and Breinig 2002).  The genetic basis of the killer 
phenotype varies; it can be chromosomal or cytoplasmic (viral dsRNA or linear dsDNA 
plasmids). Killer yeasts can produce more than one toxin, as is the case for the best 
studied organism Saccharomyces cerevisiae, which produces 5 different toxins: K1, K2 
and K28, which are cytoplasmically encoded (viral dsRNA) and KHR and KHS which 
are encoded on chromosomal DNA (Magliani et al. 1997). The mechanism of action by 
which these mycocins kill sensitive species varies. It has been shown that they can do so 
by inhibiting DNA replication, inducing changes in membrane permeability (pore 
formation) or by cell cycle arrest in G1 phase, among others (Liu et al. 2015).  
Debaryomyces hansenii is a haploid yeast that reproduces primarily by budding. It 
can be found in environments with low water activity and it is one of the most 
halotolerant yeast species (up to 25% NaCl); hence its association with cheese, meat, soil, 
wine and beer (Breuer and Harms 2006; Kumar et al. 2012). D. hansenii exhibits the 
killer phenotype and it has been found to produce and tolerate killer toxins (Banjara et al. 
2016; Breuer and Harms 2006; Santos et al. 2002). This characteristic suggests possible 
applications in food fermentations and preservation (Santos et al. 2002) and as a 
therapeutic agent (Banjara et al. 2016; Buzzini and Martini 2001).  
The genetic basis of the killer activity in Debaryomyces hansenii is unknown. 
Gunge reported the presence of plasmids, pDHL, in D. hansenii, but studies show that the 
killer activity is not associated with this plasmid; while in Kluyveromyces lactis, a linear 
dsDNA plasmid encodes the killer phenotype (Fukuda et al. 1997; Gunge et al. 1993). 
Santos and Marquina (Santos et al. 2002) reported that the killer toxin is a low molecular 
weight secreted protein encoded in chromosomal DNA, and identified 16--D-glucan 
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as the cell wall binding site for this killer toxin. However, it is unknown if additional 
toxins may exist, as is the case of Saccharomyces cerevisiae, or how the killing 
mechanism of these toxins is achieved.  
Corredor and colleagues reported high genome variability between strains of 
Debaryomyces hansenii based on chromosomal rearrangements and repeated and deleted 
sequences (Corredor et al. 2003). Banjara’s work agrees with Corredor’s findings, in so 
far as D. hansenii isolates from cheese showed consistent, reproducible variation in killer 
toxin activity, suggesting genetic differences between them. Furthermore, his work 
confirmed reports from Marquina and colleagues (Marquina et al. 2001), where it was 
revealed that the killer activity is pH and temperature dependent, with optimum 
conditions at 20C and pH 4.5, and extended the findings to multiple D. hansenii strains 
(Banjara et al. 2016).  
Mycocins produced by the cheese-derived yeast, Debaryomyces hansenii, 
represent an interesting research field due to their ease of isolation and ability to kill 
human fungal pathogens Candida albicans and Candida tropicalis in vitro. It is evident 
that more research is needed to understand the breadth of action of these mycocins 
against Candida species, so as to be able to use them as antifungal therapeutic agents for 
the possible treatment of these infections. In this study, we intend to broaden the 
knowledge on the diversity of infectious species and strains affected by this toxin, 
executing in vitro assays using previously isolated pathogenic Candida from bloodstream 
infections.  
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2.3 Materials and Methods 
Fungal Strains, growth media and culture conditions 
YEPD rich media (1% yeast extract, 2% peptone, 2% dextrose) was used to grow 
nineteen strains of Debaryomyces hansenii (Table 2.1), previously isolated from a 
variety of cheeses (Banjara et al. 2016), at room temperature. Strains were designated 
“killer” or “non-killer” based on killer activity against Candida albicans SC5314 and C. 
tropicalis NRRL 10985 (Banjara et al. 2016). Human pathogenic yeast strains were 
grown in YEPD at a temperature of 37C (Table 2.2). All yeasts were maintained on 
YEPD slants at room temperature, and at -86C in 35% glycerol. 
 
Table 2.1 Debaryomyces hansenii strains and their source of isolation (Banjara et al. 
2016).  
Strain ID Cheese Killer phenotype 
Dhans-10 Queso Authentico + 
Dhans-34 Italian Bel Pase + 
Dhans-45 Belgioloso Romano + 
Dhans-46 Wisconsin Roth Kase + 
Dhans-65 Landana 1000 days (Gouda) + 
Dhans-68 Queso Authentico – 
Dhans-72 Hennings Colby – 
Dhans-75 Italian Belpase – 
Dhans-76 Cheddar (Black Creek Smooth and Creamy) – 
Dhans-201 Bavarian Red (Rougetta) + 
Dhans-220 Italian Bel Paese (Galbani) + 
Dhans-237 Italian Bel Paese + 
Dhans-242 Parmesan (Reggiano) + 
Dhans-246 Raclette (Grand Cru) + 
Dhans-255 Provolone Cheese (Dilusso’s Wisconsin) + 
Dhans-262 Ricotta + 
Dhans-265 Wensleydale cheese (Coombe castle) + 
    
43 
Dhans-274 Blue cheese (Roth Kase Minis) + 
Dhans-276 Blue cheese (Roth Kase Minis) + 
CBS 767 Sequenced strain 
(http://genolevures.org/deha.html) 
 
 
Table 2.2 Pathogenic strains and source of isolation (Suhr 2015).  
Pathogenic species Strain ID Source of Isolation 
Candida albicans SC5314 Laboratory strain 
Candida albicans B1783 Blood  
Candida albicans B4549 Blood 
Candida tropicalis NRRL-10985 Laboratory Strain 
Candida parapsilosis B0595 Blood 
Candida parapsilosis B9860 Blood 
Candida parapsilosis B9832 Blood 
Candida parapsilosis B4075 Blood 
Candida orthopsilosis B4791 Blood 
Candida glabrata B9872 Blood 
Wickerhamomyces anomalus B1448 Blood 
 
 
Killer toxin activity assays 
Killer toxin activity of Debaryomyces hansenii killer strains was evaluated against 
pathogenic species and strains (see Table 2.2 for pathogenic strains), and against non-
killer D. hansenii strains. Killer toxin activity was determined using the streak-plate agar 
diffusion bioassay (Hodgson et al. 1995; Rosini 1983). YEPD-methylene blue agar (1% 
yeast extract, 2% peptone, 2% dextrose, 2% agar, 0.003% methylene blue and 10mM 
sodium citrate) was prepared, and pH was adjusted to 4.5 with HCl. The media was 
autoclaved and cooled to 45C. Subsequently, it was seeded with pathogenic or D. 
hansenii strains to a final density of 105 cells ml-1. Ultimately, 15 ml were poured into 
    
44 
each plate and after 5 hours, colonies of D. hansenii were streaked on the surface of the 
agar. Plates were incubated at 20C and examined daily. Toxin production, a killer 
positive reaction, was determined visually by the presence of an inhibition zone (see 
Figure 2.1), whereas the absence of the inhibition zone indicated lack of killer activity 
(Hernández et al. 2008).  
 
Cold shock killer toxin assay 
Killer toxin activity of Debaryomyces hansenii strains was evaluated against 
pathogenic species by streak-plate agar diffusion bioassay (Hodgson et al. 1995; Rosini 
1983). YEPD-methylene blue agar (1% yeast extract, 2% peptone, 2% dextrose, 2% agar, 
0.003% methylene blue and 10mM sodium citrate) was prepared, and pH was adjusted to 
4.5 with HCl. The media was autoclaved and cooled to 45C. Subsequently, it was 
seeded with pathogenic strains to a final density of 105 cells ml-1. 15 ml were poured into 
each plate and after 5 hours, colonies of D. hansenii were streaked on the surface of the 
agar. Plates were incubated at 10C for 24 hours and then placed at 20C. Indication of 
toxin production was evaluated as previously described.  
 
Plasmid curing 
Debaryomyces hansenii killer strains were grown at room temperature in YEPD 
media (1% yeast extract, 2% peptone and 2% dextrose) containing cycloheximide at 
concentrations of 1 mg ml-1 and 10 mg ml-1. Alternatively, YEPD-methylene blue agar 
(1% yeast extract, 2% peptone, 2% dextrose, 2% agar, 0.003% methylene blue and 
10mM sodium citrate) was prepared and pH was adjusted to 4.5 with HCl (Santos et al. 
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2002). The media was autoclaved and cooled to 45C. Subsequently, it was seeded 
with Candida albicans SC5314 and Candida tropicalis NRRL-10985 to a final density of 
105 cells ml-1 and cycloheximide at concentrations of 1 mg ml-1 and 10 mg ml-1 was 
added. Ultimately, 15 ml were poured into each plate and after 5 hours, colonies of D. 
hansenii (Dhans-237, Dhans-276 and CBS 767) were streaked on the surface of the agar 
and incubated at 20C. Indication of toxin production was evaluated as previously 
described. 
 
2.4 Results and Discussion 
From nineteen cheese-derived Debaryomyces hansenii strains, Banjara and 
colleagues (2016) reported fifteen strains with killing activity and four strains which 
consistently do not exhibit the killer phenotype (Table 2.1). However, they only tested 
killer activity against a single strain each of Candida albicans and Candida tropicalis. To 
expand the knowledge on the extent of pathogenic Candida species susceptible to 
Debaryomyces hansenii killer toxin, we reproduced Banjara’s assays against Candida 
albicans SC5314 and Candida tropicalis NRRL-10985, and additionally tested nine 
pathogenic Candida strains previously isolated from small bowel transplant patients with 
bloodstream infections (Suhr 2015). Our results mostly confirmed Banjara’s on C. 
albicans SC5314 and C. tropicalis NRRL-10985, with C. tropicalis more sensitive than 
C. albicans; however, strain Dhans-255 failed to kill C. tropicalis in our studies. 
Interestingly, Dhans-255 is morphologically distinct, having a rough surface when grown 
on solid culture medium, whereas the rest of the D. hansenii strains appear smooth. No 
D. hansenii strain exhibited killing activity against bloodstream isolates of Candida 
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albicans (B1783 and B4549), Candida parapsilosis (B9860, B0595, B9832 and 
B4075) and Candida orthopsilosis B4791. However, the bloodstream isolate of 
Wickerhamomyces anomalus (B1448) displayed the same sensitivity profile as Candida 
tropicalis NRRL-10985 (Table 2.3 and Table 2.4).  
 
 
 
 
 
 
 
 
 
 
 
 
    
47 
Zone 
of 
Inhibition 
   
  
 
Figure 2.1 Killer assay. YPD methylene blue plate agar seeded with Candida tropicalis 
NRRL-10985 and then streaked with killer and non-killer strains of Debaryomyces 
hansenii. Killer strains (a) show a zone of inhibition after 24 hours of incubation at 20C, 
as opposed to non-killer strains (b) where no inhibition zone is observed.  
 
a 
b 
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Table 2.3 Killer toxin activity against pathogenic species at 20C.  
Strain  Candida albicans Candida parapsilosis C. ortho C. glab C. trop W. anom 
SC5314 B1783 B4549 B9860 B0595 B9832 B4075 B4791 B9872 NRRL-10985 B1448 
Dhans-10 + – – – – – – – – + + 
Dhans-34 + – – – – – – – – + + 
Dhans-45 + – – – – – – – – + + 
Dhans-46 + – – – – – – – – + + 
Dhans-65 + – – – – – – – – + + 
Dhans-68 – – – – – – – – – – – 
Dhans-72 – – – – – – – – – – – 
Dhans-75 – – – – – – – – – – – 
Dhans-76 – – – – – – – – – – – 
Dhans-201 + – – – – – – – – + + 
Dhans-220 + – – – – – – – – + + 
Dhans-237 + – – – – – – – – + + 
Dhans-242 + – – – – – – – – + + 
Dhans-246 + – – – – – – – – + + 
Dhans-255 + – – – – – – – – – – 
Dhans-262 + – – – – – – – – + + 
Dhans-265 + – – – – – – – – + + 
Dhans-274 + – – – – – – – – + + 
Dhans-276 + – – – – – – – – + + 
C. ortho = Candida orthopsilosis, C. glab = Candida glabrata, C. trop = Candida tropicalis, W. anom = Wickerhamomyces anomalus 
+ = Killer positive, presence of an inhibition zone 
– = Killer negative, no inhibition zone observed 
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Table 2.4 Killer toxin activity against pathogenic species after 24 hour cold shock. 
Strain  Candida albicans Candida parapsilosis C. ortho C. glab C. trop W. anom 
SC5314 B1783 B4549 B9860 B0595 B9832 B4075 B4791 B9872 NRRL-10985 B1448 
Dhans-10 + – – – – – – – – + + 
Dhans-34 + – – – – – – – v + + 
Dhans-45 + – – – – – – – + + + 
Dhans-46 + – – – – – – – – + + 
Dhans-65 + – – – – – – – + + + 
Dhans-68 – – – – – – – – – – – 
Dhans-72 – – – – – – – – – – – 
Dhans-75 – – – – – – – – – – – 
Dhans-76 – – – – – – – – – – – 
Dhans-201 + – – – – – – – + + + 
Dhans-220 + – – – – – – – – + + 
Dhans-237 + – – – – – – – + + + 
Dhans-242 + – – – – – – – + + + 
Dhans-246 + – – – – – – – + + + 
Dhans-255 + – – – – – – – – – – 
Dhans-262 + – – – – – – – + + + 
Dhans-265 + – – – – – – – + + + 
Dhans-274 + – – – – – – – + + + 
Dhans-276 + – – – – – – – – + + 
C. ortho = Candida orthopsilosis, C. glab = Candida glabrata, C. trop = Candida tropicalis, W. anom = Wickerhamomyces anomalus 
+ = Killer positive, presence of an inhibition zone, – = Killer negative, no inhibition zone observed 
v = Killer activity variable 
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Candida glabrata, the second most common Candida species isolated from 
patients with candidemia (Pfaller et al. 1998), presented an interesting profile. No D. 
hansenii strains exhibited killer activity against C. glabrata when assayed at a uniform 
20C. Due to a faulty thermostat in our incubator,  we incubated the D. hansenii vs. C. 
glabrata interaction at 10C for 24 hours before we realized the thermostat flaw and 
shifted the plates to 20C for the remaining incubation. Nine strains exhibited killing 
activity against this pathogen after five days (Figure 2.2, Table 2.4). However, when 
trying to replicate this experiment we obtained a third different profile, which included 
strain Dhans-34 presenting mycocin activity contrary to the previous assay. Cold shock 
did not alter the killer profile against any other strain from that observed at 20C, 
although we observed clearer and larger zones of killing in assays that had undergone a 
cold shock. D. hansenii favors lower temperatures than the pathogenic species (Breuer 
and Harms 2006), and the cold shock may have disproportionately slowed Candida and 
Wickerhamomyces growth relative to D. hansenii, allowing more time for killer toxin 
production. C. glabrata is a distant relative to the other yeasts in this study, being closely 
related to Saccharomyces cerevisiae (Roetzer et al. 2011). Further study would be 
necessary to posit a mechanism for the observed cold shock effect, and to determine 
whether it would have any relevance in vivo.  
Nevertheless, this presents itself as an interesting research field, due to the 
similarities that Candida glabrata possesses with Saccharomyces cerevisiae (Roetzer et 
al. 2011). Considering that D. hansenii is highly influenced by higher salt concentrations, 
conducting this assay at higher NaCl concentrations would give us a better understanding 
of the killing phenotype. 
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Figure 2.2 Cold shock killer assay. YPD methylene blue plate agar seeded with 
bloodstream isolate of Candida glabrata B9872 and then streaked with strains of 
Debaryomyces hansenii. Killer strains (Dhans-237, Dhans-262 and Dhans-201) show a 
zone of inhibition after 24 hours of incubation at 10C followed 20C incubation for 
seven days, as opposed to Dhans-220 where no inhibition zone is observed.  
 
 
Killer yeasts, as a self-protection mechanism, are immune to the action of the 
toxin they produce (Bussey 1991; Schmitt and Breinig 2006).  A killer toxin assay 
performed between the D. hansenii strains that exhibited the killer phenotype and the 
ones that did not show killing activity revealed that even strains lacking killer activity in 
any of our assays possess immunity to the action of the toxins from their own species (see 
Table 2.5). In Saccharomyces cerevisiae, in which the killer phenomenon was first 
described, a wide range of phenotypes exists: killer strains which both kill and are 
resistant to killer toxin (K+R+), susceptible strains which neither kill nor are resistant (K-
R-),  neutral strains which do not kill but are resistant to mycocins (K-R+), and, rarely, 
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“suicidal” strains which kill but possess reduced immunity to their own mycocins (K+ 
R-) (Polonelli et al. 1991). Thus far we have only observed killer and neutral D. hansenii 
strains; increased sampling may reveal further diversity. 
 
Table 2.5 Killer toxin activity of Debaryomyces hansenii killer strains against D. 
hansenii non-killer strains 
Strains  Dhans-68  Dhans-72  Dhans-75  Dhans-76 
Dhans-10 – – – – 
Dhans-34 – – – – 
Dhans-45 – – – – 
Dhans-46 – – – – 
Dhans-65 – – – – 
Dhans-201 – – – – 
Dhans-220 – – – – 
Dhans-237 – – – – 
Dhans-242 – – – – 
Dhans-246 – – – – 
Dhans-255 – – – – 
Dhans-262 – – – – 
Dhans-265 – – – – 
Dhans-274 – – – – 
Dhans-276 – – – – 
                   – = Killer negative, no inhibition zone observed 
 
Debaryomyces hansenii possesses three plasmids: pDHL1 pDHL2 and pDHL3 
(Gunge et al. 1993). Plasmid pDHL1 is highly homologous to the plasmid pGKL1 
present in Kluyveromyces lactis, which encodes a protein that is the source of the killer 
phenotype (Fukuda et al. 1997). Killer yeasts can be cured of plasmid-encoded killer 
phenotype by a series of methods that include, but are not limited to, exposure to high 
temperatures, ultraviolet light and cycloheximide (Santos et al. 2002). To determine 
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whether the killer activity of any D. hansenii strain was encoded on a plasmid, strains 
were grown with cycloheximide to eliminate cytoplasmic plasmids. Attempts to grow D. 
hansenii in a media containing cycloheximide were unsuccessful as a result of protein 
biosynthesis inhibition caused by cycloheximide. Alternative treatment in effort to cure 
Debaryomyces hansenii’s plasmid with cycloheximide was ineffective (see Figure 2.3). 
Our results concur with those of Buzzini and Martini (2000) and Santos (2002)(Buzzini 
and Martini 2000; Santos et al. 2002), in which treated Debaryomyces hansenii showed 
no reduced activity during killer activity assays on methylene blue plates seeded with a 
susceptible species (e.g. Candida tropicalis). Killer strains retaining the killer phenotype 
after treatment suggest that the killer phenotype is not associated with the presence of a 
plasmid. Further tests could be performed to ensure absence of plasmids in treated cells; 
however, all available evidence to date supports the hypothesis of a chromosomal 
location for D. hansenii mycocins-encoding gene(s). 
Significantly, studies on killer and susceptible yeasts show that strain sensitivity 
can be influenced, among other things, by the nature of the cell wall and physiological 
niche (Hodgson et al. 1995). Considering Candida as an opportunistic pathogen, but also 
a commensal organism of the human microbiota, virulence and other physiological 
parameters differ between isolates. The correlation, if any, between virulence in a human 
host and resistance or susceptibility to killer toxins remains unknown. Recent 
bloodstream isolates such as C. albicans B1783 and B4549 might be expected to be more 
aggressive and robust than C. albicans SC5314, which has been subcultured for 30+ 
years since its original isolation from a patient with disseminated candidiasis.  The 
inability of any of our D. hansenii killer strains to kill the bloodstream C. albicans (and 
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the ability to kill SC5314) demonstrate clearly the need to screen a broad range of 
potentially susceptible isolates as well as killer isolates. Candidemia is a serious life-
threatening infection that can affect the brain, heart and bones (Pappas 2006), against 
which new therapeutic options are desperately needed. Further sampling may reveal 
strains or combinations of strains of killer yeasts with greater efficacy against pathogenic 
Candida, while purification of the mycocins(s) from D. hansenii and characterization of 
the mode of action may yield a usable antimycotic agent.  
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Figure 2.3 Plasmid-curing killer assay. YPD methylene blue plate agar seeded with 
Candida tropicalis NRRL-10985 and cycloheximide at concentrations of 1 mg ml-1 (a) 
and 10 mg ml-1 (b), subsequently streaked with killer strains of Debaryomyces hansenii 
show a zone of inhibition after 24 hours of incubation at 20C.  
 
 
a 
b 
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Chapter 3 
Towards understanding the genetic basis of Debaryomyces hansenii 
killer toxin 
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3.1 Abstract 
Yeasts can produce toxic proteins or glycoproteins, i.e. “mycocins” or “killer 
toxins”, which are able to kill sensitive yeast species. The production of mycocins, first 
discovered in Saccharomyces cerevisiae, is a widespread phenomenon among various 
yeast genera. Debaryomyces hansenii is one of the most halotolerant yeast species, hence 
its association with preserved and fermented foods. Strains of D. hansenii have been 
shown to kill potentially pathogenic yeasts, including strains of Candida albicans, 
Candida glabrata, Candida tropicalis, and Wickerhamomyces anomalus at optimum 
conditions of 20C and pH 4.5. The genetic basis and mechanism of action of this 
toxin(s) are unknown. Cycloheximide treatment of D. hansenii prior to or during killer 
activity assays on methylene blue plates seeded with Candida tropicalis does not reduce 
mycocin activity, suggesting that the toxin is not cytoplasmically-encoded, as are several 
characterized yeast killer toxins, but chromosomal. To understand the nature of these 
toxins, 2x250 paired end Illumina sequencing, averaging 100x coverage (range: 48x - 
145x), was performed on 7 killer and 3 non-killer strains of Debaryomyces hansenii 
previously isolated from different types of cheese. Numerous differences between D. 
hansenii strains were identified that may account for the difference in toxicity. Genome 
analysis detected 48 DNA regions, ranging from 31-3434 bp, unique to all sequenced 
killer strains and missing from non-killer strains, and 32 regions present in all non-killers 
and missing from killer strains. Five different regions have been chosen for their possible 
killer toxin role, including predicted members of the ABC-ATPase and major facilitator 
superfamilies, cytochrome P450s, and interestingly, a multidrug resistance protein. 
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Primers were designed and construction of a mutant has begun so as to be one step 
closer to understanding the relationship between these regions and the killer toxin 
production.  
 
3.2 Introduction 
The killer phenomenon among yeasts is fairly common, having been reported in 
more than 90 species, across more than 20 genera (Walker et al. 1995; Young and Yagiu 
1978). Killer yeasts produce toxic proteins that are able to kill susceptible species. The 
genetic basis of these toxins can be encoded on chromosomal genes or in the cytoplasm 
as dsRNA virus-like particles or linear dsDNA plasmids (Magliani et al. 1997). The 
modes of action to achieve the lethal effect vary and, usually, as a self defense 
mechanism they possess intrinsic immunity to the action of their own mycocin (Schmitt 
and Breinig 2002). However, there exist situations where mycocin concentration prevails 
and this immunity is overcome; so called suicidal mutants (K+ R–) (Polonelli et al. 
1991). Young stated that while all killer systems vary, they have a proteinaceous 
compound crucial to the killer activity that is common among them, and yeasts from the 
same species can produce various toxins with distinctive modes of action (Young and 
Yagiu 1978). 
The first requirement to kill a susceptible organism is commonly a cell wall 
receptor on the sensitive cell that interacts with the killer toxin, usually chitin, -glucans 
or mannoproteins, and suggestions exist about the existence of a second receptor on the 
plasma membrane that facilitates absorption (Magliani et al. 1997; Schmitt and Breinig 
2006). Subsequently, they can achieve the lethal effect by different biological pathways. 
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K1 and K2 toxin produced by Saccharomyces cerevisiae induce changes in the 
permeability of the membrane; by forming ion channels an uncontrolled leakage of 
protons, potassium ions, amino acids and ATP molecules will occur causing cell death 
(Marquina et al. 2002). Alternatively, the S. cerevisiae K28 toxin releases a signal that 
results in inhibition of DNA synthesis, which produces the lethal effect (Liu et al. 2015).  
Several authors explain the killer activity that Kluyveromyces lactis exhibits towards 
Saccharomyces cerevisiae as an attack on the tRNA leading to cell death (Frohloff et al. 
2001; Jablonowski and Schaffrath 2007; Jablonowski et al. 2006). Additionally, KP4 
toxin produced by Ustilago maydis inhibits growth and division of susceptible cells by 
blocking calcium uptake (Gage et al. 2001). 
Debaryomyces hansenii is a haploid yeast that reproduces by multilateral budding 
(Breuer and Harms 2006) and is an extremophile, one of the most halotolerant yeast 
species, growing in media containing up to 4M NaCl (Breuer and Harms 2006). It was 
originally isolated from saline environments (Kumar et al. 2012) and is the most common 
yeast found in cheese (Banjara et al. 2015) and in dry–cured meat products (Andrade et 
al. 2009). D. hansenii can also be found in other environments with low water activity; 
hence its association with soil, fruits, wine and beer (Breuer and Harms 2006; Kumar et 
al. 2012). 
Debaryomyces hansenii exhibits the killer phenotype against strains of Candida 
albicans and Candida tropicalis in vitro (Banjara et al. 2016) and it has been found to 
tolerate killer toxins from Kluyveromyces lactis, Candida zeylanoides and Trichosporon 
cutaneum (Fukuhara 1995; Nout et al. 1997). The genetic basis of the killer activity in 
Debaryomyces hansenii remains unexplored. Gunge reported the presence of three 
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plasmids, pDHL1, pDHL2 and pDHL3, in D. hansenii (Gunge et al. 1993), and 
discovered that plasmid pDHL3 is fundamental for pDHL1 and pDHL2 replication 
(Fukuda et al. 1997). Killer yeasts can be cured of plasmid-encoded killer phenotype by a 
series of methods that include exposure to high temperatures, ultraviolet light and 
cycloheximide (Fukuhara 1995; Santos et al. 2002). Assays performed on D. hansenii 
strains suggest that the killer character in D. hansenii is not cytoplasmically encoded, but 
chromosomally. Corredor and colleagues reported high genome variability between 
strains of D. hansenii based on chromosomal rearrangements and repeated and deleted 
sequences (Corredor et al. 2003), and Banjara’s work agrees in so far as D. hansenii 
isolates from cheese showed consistent, reproducible variation in killer toxin activity 
(Banjara et al. 2016).  
Santos and Marquina (Santos et al. 2002) described the killer toxin produced by 
Debaryomyces hansenii as a low molecular weight secreted protein, and identified 16-
-D-glucan as the cell wall binding site for this killer toxin. It is unknown if additional 
toxins may exist and how the killing mechanism of these toxins is achieved. Furthermore, 
Marquina and colleagues (Marquina et al. 2001), and Banjara’s work revealed that the 
killer activity is pH and temperature dependent, with optimum conditions at 20C and pH 
4.5 (Banjara et al. 2016).  
It is evident that more research is needed to understand the mechanisms by which 
Debaryomyces hansenii mycocins achieve the lethal effect, so as to take advantage of its 
full biotechnological potential. In this study we intend to explore the genome so as to be 
able to look for possible regions or genes that could be responsible for toxin production.  
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3.3 Materials and Methods 
Organisms, growth media and culture conditions 
YEPD rich media (1% yeast extract, 2% peptone, 2% dextrose) at room 
temperature was used to grow 10 selected Debaryomyces hansenii strains – seven killer 
and three non-killer – previously isolated from different type of cheeses (Banjara et al. 
2016). D. hansenii strains have been deposited at the CBS-KNAW Fungal Biodiversity 
Centre – an institute of the Royal Netherlands Academy of Arts and Sciences (see Table 
3.1 for Debaryomyces hansenii strains and accession numbers).  
 
DNA isolation 
High quality DNA extraction for sequencing of Debaryomyces hansenii strains, 
and for amplification of the Candida albicans hexokinase gene (HEX1) was 
accomplished using a modified version of the QIAGEN Genomic Tip 100/G and 
QIAGEN buffer methodology (QIAGEN, Germantown, MD). The yeast protocol from 
the QIAGEN Genomic DNA Handbook was followed with the additional use of 65–70C 
incubation while pelleting, and the addition of beads, sand and sonication in the protease 
pelleting step to increase yield. DNA extraction for PCR assays was performed using a 
modified version of the Bust n’ Grab method (Harju et al. 2004), in which the freezing (-
80C for 5 minutes) and heating (95C for 1 minute) steps were repeated twice. 
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Genome sequencing and analysis 
Illumina sequencing, 2 x 250 paired end reads to an estimated 50X coverage, was 
performed on 7 killer and 3 non-killer, arbitrarily selected, Debaryomyces hansenii 
strains at Michigan State University, Research Technology Support Facility (RTSF). 
Sequences have been deposited with the National Center for Biotechnology Information 
(Table 3.1). Quality controlled reads were assembled with SPAdes (Bankevich et al. 
2012) version 3.1.0 with kmers 21, 33, 55, and 77. Scaffolds longer than 1 kb were 
retained for downstream analysis.  Using core eukaryotic genes, all genomes were 
estimated to be >94.35% complete (Parra et al. 2007).  Genomes were compared in a 
pairwise fashion using Mugsy (Angiuoli and Salzberg 2011).  Outputs from Mugsy were 
parsed with custom perl scripts to identify genome regions exclusive to killer or non-
killer strains.  The Candida genome database (http://www.candidagenome.org), NCBI 
(http://www.ncbi.nlm.nih.gov), and Génolevures (Sherman et al. 2009) were used to 
assign putative functions to sequences of interest.  
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Table 3.1 Debaryomyces hansenii strains, killer toxin activity, accession numbers 
and source of isolation.  
Strain ID CBS accession 
number 
BioSample 
Objects 
Cheese Killer 
Activity 
Dhans-68 14260 SAMN04420253 Queso Authentico – 
Dhans-72 14261 SAMN04420254 Hennings Colby – 
Dhans-76 14269 SAMN04420255 Cheddar (Black Creek 
Smooth and Creamy) 
– 
Dhans-220 14262 SAMN04420256 Italian Bel Paese 
(Galbani) 
+ 
Dhans-237 14264 SAMN04420257 Italian Bel Paese + 
Dhans-242 14266 SAMN04420258 Parmesan (Reggiano) + 
Dhans-246 14265 SAMN04420259 Raclette (Grand Cru) + 
Dhans-255   Provolone Cheese 
(Dilusso’s Wisconsin) 
–1 
Dhans-274 14267 SAMN04420260 Blue cheese (Roth Kase 
Minis) 
+ 
Dhans-276 14268 SAMN04420261 Blue cheese (Roth Kase 
Minis) 
+ 
+ = Killer positive, presence of an inhibition zone 
– = Killer negative, no inhibition zone observed 
1Dhans-255 was originally identified as killer (Banjara et al. 2016), but was not observed 
to kill in our assays. It also exhibited morphological variation from the other D. hansenii 
strains and the DNA sequence quality was low, so this strain was excluded from further 
analysis and was not deposited with CBS or NCBI. 
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Construction of the gene knockout cassettes 
Polymerase chain reaction (PCR) was used to assemble gene knockout cassettes 
by fusing noncoding DNA upstream and downstream of the gene of interest (genes 
unique to either killer or non-killer strains) with DNA encoding the Candida albicans 
HEX1 gene, following the protocol outlined by Hallen and Trail (2008). The 1000 bp 
upstream and downstream of genes of interest (Table 3.2) were downloaded from 
Génolevures (Sherman et al. 2009) and trimmed as necessary to ensure these regions 
contained no predicted proteins. Primers were designed using Lasergene Version 12.0 
(DNASTAR, Madison, WI) (Table 3.4), and the presence of primer sequences in the 
relevant D. hansenii strains (killer or non-killer, as appropriate) was confirmed using 
SeqMan NGen version 12.0 (DNASTAR). The 5’ ends of primers nearest to the targeted 
gene (upstream reverse primers and downstream forward primers; Table 3.4 and Figure 
3.2) included an additional 17 to 23 nucleotides complementary to the C. albicans HEX1 
gene. 
PCR reactions for amplification of noncoding DNA regions (upstream and 
downstream) were performed with the following conditions: initial denaturation at 95 °C 
for 3 min, followed by 34 cycles at 95°C for 30 sec, 55°C for 30 sec, and 72°C for 1 min, 
and a final extension step of 72°C for 5 min. Each reaction contained 12.5 l of Maxima 
Hot Start Green master mix DNA polymerase (ThermoScientific), 2 l of each 
oligonucleotide primer, 7.5 l of molecular biology-grade water and 1 l DNA template 
for a final volume of 25 l. PCR was performed on Dhans-237 and Dhans-274 to amplify 
regions unique to killer strains, and on Dhans-68 and Dhans-76 for regions unique to 
non-killers. HEX1 was amplified from C. albicans SC-1543 using 0.25 l of TaKaRa Ex 
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Taq polymerase, 5 l of 10X Ex Taq Buffer (Mg2+ plus), 4 l of dNTP Mixture, 5 l 
each of primers 1 and 2 (Table 3.4), 28.75 l of molecular biology-grade water, and 2l 
DNA template for a final volume of 50 l), using the amplification conditions described 
above. 
 
 
Table 3.2 Chosen genes and their predicted function. 
ID of Chosen Regions Primer ID Conserved Domains 
DEHA2D01056g D1056 The Major Facilitator Superfamily 
DEHA2G14916g  DoubleGene Multidrug resistance protein 
DEHA2G14894g DoubleGene ABC-2 type transporter 
DEHA2E00220g E220 No prediction 
DEHA2G00110g G110 Cytochrome P450 
ID of chosen regions is the gene ID from Génolevures, and is read as follows: 
DEHA2D01056g is Debaryomyces hansenii (strain CBS 767), sequence build 2, 
chromosome D, gene 01056, from genomic DNA. Primer ID is derived from the 
chromosome and gene number, except for “DoubleGene”: genes G14916 and G14894 are 
adjacent, so primers were designed upstream and downstream of the pair, to knock both 
out simultaneously. 
 
 
PCR products from the upstream region and the HEX1 gene were combined with 
an additional round of PCR using primer 1 and upstream forward primers (primers 5, 9, 
13, and 17). Downstream region and HEX1 gene were combined with an additional round 
of PCR using primer 2 and downstream reverse primers (8, 12, 16, and 20). Fusion of the 
upstream-HEX1 and downstream-HEX1 was achieved using primers 5 and 8, using an 
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adaptation of the protocol for Expand Long-Template Polymerase (Roche Applied 
Science, Indianapolis, IN), as outlined in Table 3.3. PCR mixture for amplification of 
Candida albicans HEX1 gene and for assembling the knockout cassette contained 0.25 l 
of TaKaRa Ex Taq polymerase, 5 l of 10X Ex Taq Buffer (Mg2+ plus), 4 l of dNTP 
Mixture, 5 l of each oligonucleotide primer, 28.75 l of molecular biology-grade water, 
and 2l DNA template for a final volume of 50 l. Bands were purified as needed using 
the Wizard® SV Gel and PCR Clean-Up System (Promega, Madison, WI) following 
manufacturer’s instructions. All amplifications were carried out on a T100 Thermal 
Cycler (Bio-Rad, Hercules, CA, USA) and PCR products were visualized by ethidium 
bromide staining on an agarose gel. Figure 3.2 shows a schematic of this protocol. 
 
 
Table 3.3 PCR expansion protocol 
PCR stage Temperature Time 
Denaturation 95C 4 min 
Denaturation 95C 30 sec 
Annealing 52C 30 sec 
Extension 72C 2:30 min 
               GOTO step 2 10 cycles 
Denaturation 95C 30 sec 
Annealing 52C 30 sec 
Extension 72C 2:30 min +5 s per cycle 
                GOTO step 6  25 cycles 
Extension 72C 7:00 min 
Hold 4C  
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3.4 Results and Discussion  
High quality DNA from Debaryomyces hansenii killer (Figure 3.1) and non-killer 
strains (not shown) was successfully extracted and used for whole genome sequencing.  
 
 
Figure 3.1 DNA isolation. High-quality DNA extraction from Debaryomyces hansenii 
strains. From left to right, killer strains Dhans-242, Dhans-220, Dhans-274, Dhans-276, 
Dhans-265 (not sequenced), Dhans-246, Dhans-255 and Dhans-237. 
 
Genome analysis identified 48 DNA regions unique to all sequenced killer strains 
and missing from non-killer strains, and 32 regions present in all non-killers and missing 
from killer strains, ranging from 31-3434 bp. While single nucleotide polymorphisms 
(SNPs) and other genetic features may influence killer status, we chose to focus on larger 
differences involving gene presence and absence. The Candida genome database 
(http://www.candidagenome.org) was used to find the designated regions where the 
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identified sequence was localized. Subsequently, NCBI (http://www.ncbi.nlm.nih.gov) 
was used to find the predicted functions or conserved domains of the sequences (Table 
3.2). We found four distinct regions that look promising, that include a predicted member 
of the major facilitator superfamily (MFS), which are a group of transporters (Pao et al. 
1998); an ABC-2 type transporter (Reizer et al. 1992); cytochrome P450 which is 
involved in the production and degradation of toxic compounds (Ogu and Maxa 2000), 
and a multidrug resistance protein that is known to be involved in the export of toxins 
(Blackmore et al. 2001). Additionally, we selected one gene that had no predicted 
function and appears to have no homolog in the databases outside of D. hansenii. 
Génolevures provided the genetic elements of the chosen sequences (Sherman et al. 
2009). Finally, primers were built for the chosen regions using DNASTAR software 
(Table 3.4) and overlaps were built to complement the HEX1 gene from Candida 
albicans, which allows them to fuse in a separate PCR reaction. 
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Table 3.4 PCR primers designed with DNASTAR® for gene knockout. 
Primer 
no. 
Primer ID Sequence 
1 Hex1XformF 5’-cccgatccttggtgctc-3’  
2 Hex1XformR 5’-ccccttccttaatttgtgtttgat-3’ 
3 Hex1InternalF 5’-ccaggggatatgatgttgtag-3’ 
4 Hex1InternalR 5’-ctgtggagctgggagtatttc-3’ 
5 E220UpF 5’-acgcagggtaaagtatcaatcca-3’ 
6 E220UpR 5’-atcaaacacaaattaaggaaggg_gtgcgcaagccaaaagtgt-3’ 
7 E220DownF 5’-gagcaccaaggatcggg_tctacgaaatgaatgaccta-3’ 
8 E220DownR 5’-aatatgtgttctaaccttgatg-3’ 
9 G110UpF 5’-ctattctccattcgcatcacaac-3’ 
10 G110UpR 5’-atcaaacacaaattaaggaagggg_ccagaaaaagggcagcatagt-3’ 
11 G110DownF 5’-gagcaccaaggatcggg_cgcgccgcatcaacaga-3’ 
12 G110DownR 5’-aggcaacgagtcccgaacataa-3’ 
13 D1056UpF 5’-aagccagggatgttagg-3’ 
14 D1056UpR 5’-atcaaacacaaattaaggaagg_ggcggctgctgggtttat-3’ 
15 D1056DownF 5’-gagcaccaaggatcggg_atattaactaaagccgcagagact-3’ 
16 D1056DownR 5’-aaggggatatgaataacagacaac-3’ 
17 DoublegeneUpF 5’-gaagccggacagaaggtaga-3’ 
18 DoublegeneUpR 5’-atcaaacacaaattaaggaagggg_tatatgttttaatcggagaa-3’ 
19 DoublegeneDownF 5’-gagcaccaaggatcggg_taaaatcggatgcaataagaaatg-3’ 
20 DoublegeneDownR 5’-aaggcgctcaatccaactc-3’ 
Bold segments in the UpR and DownF primers are complementary to the HEX1 gene 
from Candida albicans. 
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Step 1 
Step 2 
 
 
 
 
 
 
 
 
Figure 3.2 Schematic of PCR-based transformation. Amplifying noncoding DNA, 
both upstream and downstream, of the gene of interest will result in the construction of 
E220 mutants. The PCR products of the upstream and downstream regions have 
overlaps built onto the primers of the HEX1 gene allowing them to fuse on an additional 
round of PCR. A separate PCR on Candida albicans results in amplification of the HEX1 
gene. An additional PCR is used to fuse together the three product: upstream, 
downstream and HEX1. E220 is replaced by double-crossover integration of the HEX1 
gene into the homologous portion of the genome.  
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Using Candida albicans HEX1 gene as a selectable marker will allow us to 
identify the transformants by their color on CHROMagar™ Candida (Niimi et al. 2001): 
green colonies for colonies expressing C. albicans hexokinase, and purple for wild-type 
D. hansenii. Yeast transformations are usually performed using antibiotic resistance 
markers (Kaster et al. 1984). However, using hygromycin B as a resistant marker in 
yeasts is typically difficult. Chand-Goyal and Eckert (1996) found that D. hansenii is 
resistant to the antibiotic and were not able to transform the yeast (Chand-Goyal and 
Eckert 1996). Nonetheless, Ricaurte (1999) found strains of D. hansenii that were 
susceptible to 100 g/ml of Hyg and successfully transformed the yeast (Ricaurte and 
Govind 1999). Effective transformation of D. hansenii using C. albicans HEX1 gene as a 
marker will be a novelty and will make transformations of non-albicans Candida and D. 
hansenii strains uncomplicated due to color identification.   
Upstream and downstream regions for the five genes (four genetic regions) we 
selected have all been amplified from the appropriate killer or non-killer D. hansenii 
strains, and HEX1 has been amplified from C. albicans. To construct the transformation 
cassette, PCR products from the upstream and downstream regions were amplified 
together with the HEX1 PCR product from C. albicans. Reactions were performed in 
which all three products (upstream, downstream and HEX1), were present, and in which 
only two products were present (upstream and HEX1, downstream and HEX1). We have 
assembled the transformation cassette for E220 (predicted protein of unknown function), 
amplifying the upstream and the downstream region from Debaryomyces hansenii strain 
Dhans-68. The PCR product of the Hex1 gene has a size of 1,686 bp, the upstream 
product is 507 bp and the downstream product is 423 bp. Using a GeneRuler 1kb Plus 
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DNA Ladder from Thermo Scientific, we estimated the size of the products. C. 
albicans Hex1 gene estimate size is around 2,000 bp, the upstream region is around 500 
bp and the downstream region is around 400 bp (Figure 3.3). Two separate PCR 
reactions were done to combine the upstream region with the Hex1 gene and the Hex1 
gene with the downstream region. An additional PCR fused the last two products so as to 
incorporate the Hex1 gene with the upstream and downstream. This final product 
presented a size of around 3,000 bp, which is congruent with the expected outcome of 
2,616 bp (Figure 3.4).   
 
3.5 Future Directions 
Experiments are underway to incorporate the transformed DNA into a cell. We 
are following an adaptation of Hallen-Adams et al. 2011, where the first step is to have 
enzymes destroy the cell walls of the yeast. Subsequently, 30% PEG 8000 and sorbitol 
solutions will force the DNA into the cell where, in some cells, it will integrate into the 
nucleus. A high sugar treatment for 24 hours will allow the cell walls to re-form and 
plating in CHROMagar™ will allow us to identify transformed colonies by their green 
color (Hallen-Adams et al. 2011).  
Preliminary results show that using a high sugar solution results in an excessive 
amount of yeast recovery, and YEPD media seems to be more adequate for yeast cells 
regeneration. Additionally, a spread plate technique (100 l) in CHROMagar™ results in 
a complete growth of the yeast in the plate, where isolation of a single colony is 
impossible. A streak plate technique has shown to be more adequate for isolation of 
colonies. If green colonies are found the next step will be to confirm the presence of the 
    
77 
HEX1 gene performing a PCR reaction with primers 3 and 4, and using up- and 
downstream primers to confirm the presence of the transformed DNA. Furthermore, 
southern blot will help us to confirm the presence of specific DNA segments in our 
samples. If green colonies were not present, electroporation would be our next go to 
transformation protocol for incorporation of the construct into the cell.  
Once the deletion/insertion of genes is confirmed, killer assays will be performed 
against Candida albicans and Candida tropicalis. These assays will help us establish the 
relationship between the gene of interest and the killer toxin activity. If deleting a gene on 
a killer strain results in the absence of the killer phenotype, this suggest that the gene 
deleted is somehow involved with the killer toxin production. Studying the genetic basis 
of these toxins allows us to understand how the killing mechanism works, and could even 
tell us the gene or genes responsible, if any, for the toxin production.  
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Figure 3.3 PCR products. A 1kb Plus DNA Ladder (1) was used to determine the size 
of the products. Candida albicans HEX1 gene (2 and 3) is close to ~1,686 bp. The 
upstream (4) and downstream (5) regions of strain Dhans-68 have a size of ~507 and 
~423 bp respectively. Lane 6 shows the water control. 
 
 
Figure 3.4 Gene replacement cassette. A 1kb marker (1) was used to determine the size 
of the products. Lane 2 shows the product from the Dhans-68 transformation (~3k bp) 
and lane 3 represents the water control.  
1         2       3        4                  5                6 
1         2                   3    
    
79 
3.7 References 
Andrade, M., Rodríguez, M., Casado, E., Bermúdez, E. and Córdoba, J. 2009. 
Differentiation of yeasts growing on dry-cured Iberian ham by mitochondrial 
DNA restriction analysis, RAPD-PCR and their volatile compounds production. 
Food microbiology 26:578-586. 
Angiuoli, S. V. and Salzberg, S. L. 2011. Mugsy: fast multiple alignment of closely 
related whole genomes. Bioinformatics 27:334-342. 
Banjara, N., Nickerson, K. W., Suhr, M. J. and Hallen-Adams, H. E. 2016. Killer toxin 
from several food-derived Debaryomyces hansenii strains effective against 
pathogenic Candida yeasts. International Journal of Food Microbiology. 
Banjara, N., Suhr, M. J. and Hallen-Adams, H. E. 2015. Diversity of yeast and mold 
species from a variety of cheese types. Current microbiology 70:792-800. 
Bankevich, A., Nurk, S., Antipov, D., Gurevich, A. A., Dvorkin, M., Kulikov, A. S., 
Lesin, V. M., Nikolenko, S. I., Pham, S., Prjibelski, A. D., Pyshkin, A. V., 
Sirotkin, A. V., Vyahhi, N., Tesler, G., Alekseyev, M. A. and Pevzner, P. A. 
2012. SPAdes: A New Genome Assembly Algorithm and Its Applications to 
Single-Cell Sequencing. Journal of Computational Biology 19:455-477. 
Blackmore, C. G., McNaughton, P. A. and Veen, H. W. V. 2001. Multidrug transporters 
in prokaryotic and eukaryotic cells: physiological functions and transport 
mechanisms. Molecular membrane biology 18:97-103. 
Breuer, U. and Harms, H. 2006. Debaryomyces hansenii—an extremophilic yeast with 
biotechnological potential. Yeast 23:415-437. 
    
80 
Chand-Goyal, T. and Eckert, J. 1996. Studies on transformation of Candida oephila 
and Debaryomyces hansenii with plasmids. Phytopathology 86:S34. 
Corredor, M., Davila, A.-M., Casarégola, S. and Gaillardin, C. 2003. Chromosomal 
polymorphism in the yeast species Debaryomyces hansenii. Antonie van 
Leeuwenhoek 84:81-88. 
Frohloff, F., Fichtner, L., Jablonowski, D., Breunig, K. D. and Schaffrath, R. 2001. 
Saccharomyces cerevisiae Elongator mutations confer resistance to the 
Kluyveromyces lactis zymocin. The EMBO Journal 20:1993-2003. 
Fukuda, K., Maebuchi, M., Takata, H. and Gunge, N. 1997. The linear plasmid pDHL1 
from Debaryomyces hansenii encodes a protein highly homologous to the 
pGKL1-plasmid DNA polymerase. Yeast 13:613-20. 
Fukuhara, H. 1995. Linear DNA plasmids of yeasts. FEMS microbiology letters 131:1-9. 
Gage, M. J., Bruenn, J., Fischer, M., Sanders, D. and Smith, T. J. 2001. KP4 fungal toxin 
inhibits growth in Ustilago maydis by blocking calcium uptake. Molecular 
microbiology 41:775-785. 
Gunge, N., Fukuda, K., Morikawa, S., Murakami, K., Takeda, M. and Miwa, A. 1993. 
Osmophilic linear plasmids from the salt-tolerant yeast Debaryomyces hansenii. 
Current genetics 23:443-449. 
Hallen, H. E. and Trail, F. 2008. The L-type calcium ion channel cch1 affects ascospore 
discharge and mycelial growth in the filamentous fungus Gibberella zeae 
(anamorph Fusarium graminearum). Eukaryotic cell 7:415-424. 
    
81 
Hallen-Adams, H., Cavinder, B. and Trail, F. 2011. Fusarium graminearum from 
Expression Analysis to Functional Assays. Pages 79-101 in: Fungal Genomics. J.-
R. Xu and B. H. Bluhm, eds. Humana Press. 
Harju, S., Fedosyuk, H. and Peterson, K. R. 2004. Rapid isolation of yeast genomic 
DNA: Bust n'Grab. BMC biotechnology 4:8. 
Jablonowski, D. and Schaffrath, R. 2007. Zymocin, a composite chitinase and tRNase 
killer toxin from yeast. Biochemical Society Transactions 35:1533-1537. 
Jablonowski, D., Zink, S., Mehlgarten, C., Daum, G. and Schaffrath, R. 2006. tRNAGlu 
wobble uridine methylation by Trm9 identifies Elongator's key role for zymocin‐
induced cell death in yeast. Molecular microbiology 59:677-688. 
Kaster, K. R., Burgett, S. G. and Ingolia, T. D. 1984. Hygromycin B resistance as 
dominant selectable marker in yeast. Current genetics 8:353-358. 
Kumar, S., Randhawa, A., Ganesan, K., Raghava, G. P. S. and Mondal, A. K. 2012. Draft 
genome sequence of salt-tolerant yeast Debaryomyces hansenii var. hansenii 
MTCC 234. Eukaryotic cell 11:961-962. 
Liu, G.-L., Chi, Z., Wang, G.-Y., Wang, Z.-P., Li, Y. and Chi, Z.-M. 2015. Yeast killer 
toxins, molecular mechanisms of their action and their applications. Critical 
reviews in biotechnology 35:222-234. 
Magliani, W., Conti, S., Gerloni, M., Bertolotti, D. and Polonelli, L. 1997. Yeast killer 
systems. Clinical microbiology reviews 10:369-400. 
Marquina, D., Barroso, J., Santos, A. and Peinado, J. 2001. Production and characteristics 
of Debaryomyces hansenii killer toxin. Microbiological research 156:387-391. 
    
82 
Marquina, D., Santos, A. and Peinado, J. 2002. Biology of killer yeasts. International 
Microbiology 5:65-71. 
Niimi, K., Shepherd, M. G. and Cannon, R. D. 2001. Distinguishing Candida species by 
β-N-acetylhexosaminidase activity. Journal of clinical microbiology 39:2089-
2097. 
Nout, M., Platis, C. and Wicklow, D. 1997. Biodiversity of yeasts from Illinois maize. 
Canadian journal of microbiology 43:362-367. 
Ogu, C. C. and Maxa, J. L. 2000. Drug interactions due to cytochrome P450. Proceedings 
(Baylor University. Medical Center) 13:421-423. 
Pao, S. S., Paulsen, I. T. and Saier, M. H. 1998. Major facilitator superfamily. 
Microbiology and Molecular Biology Reviews 62:1-34. 
Parra, G., Bradnam, K. and Korf, I. 2007. CEGMA: a pipeline to accurately annotate core 
genes in eukaryotic genomes. Bioinformatics 23:1061-1067. 
Polonelli, L., Conti, S., Gerloni, M., Magliani, W., Chezzi, C. and Morace, G. 1991. 
Interfaces of the yeast killer phenomenon. Critical reviews in microbiology 18:47-
87. 
Reizer, J., Reizer, A. and Saier, M. H. 1992. A new subfamily of bacterial ABC‐type 
transport systems catalyzing export of drugs and carbohydrates. Protein Science 
1:1326-1332. 
Ricaurte, M. L. and Govind, N. S. 1999. Construction of plasmid vectors and 
transformation of the marine yeast Debaryomyces hansenii. Marine 
Biotechnology 1:15-19. 
    
83 
Santos, A., Marquina, D., Barroso, J. and Peinado, J. 2002. (1→ 6)‐β‐D‐glucan as the 
cell wall binding site for Debaryomyces hansenii killer toxin. Letters in applied 
microbiology 34:95-99. 
Schmitt, M. J. and Breinig, F. 2002. The viral killer system in yeast: from molecular 
biology to application. FEMS Microbiology Reviews 26:257-276. 
Schmitt, M. J. and Breinig, F. 2006. Yeast viral killer toxins: lethality and self-protection. 
Nature Reviews Microbiology 4:212-221. 
Sherman, D. J., Martin, T., Nikolski, M., Cayla, C., Souciet, J.-L. and Durrens, P. 2009. 
Genolevures: protein families and synteny among complete hemiascomycetous 
yeast proteomes and genomes. Nucleic acids research 37:D550-D554. 
Walker, G. M., Mcleod, A. H. and Hodgson, V. J. 1995. Interactions between killer 
yeasts and pathogenic fungi. FEMS Microbiology Letters 127:213-222. 
Young, T. and Yagiu, M. 1978. A comparison of the killer character in different yeasts 
and its classification. Antonie van Leeuwenhoek 44:59-77. 
 
 
